CD19 and acute lymphoblastic leukemia: In this issue of the JCI, Aminov, Giricz, and co-authors found that B-ALL cell lines expanding through CD19-targeted therapy expressed lower levels of CD19 RNA and protein than did parental cells, observations they extended to nine pediatric patients with B-ALL relapsing after CD19 CAR-T (3).